By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
The private, European-based company widens its base with new approaches and technologies for treating pain and, now, related conditions.
If you can spot it through the dense cloud of opioid- epidemic news currently emanating from the United States, some companies are developing new modalities for the treatment of pain. Among them, Grünenthal is a recognized catalyst. Like other pain-focused companies, Grünenthal has mainly pursued innovation with “abuse-deterrent” technologies and products for the prescription-opioid market. But now, along with a slew of partners, the company is identifying, studying, and targeting specific types, or “segments,” of pain, using new therapeutic mechanisms and technologies — even developing novel, non-opioid applications for its abuse-deterrent INTAC platform. It is also moving beyond pain into other, “adjacent,” areas.